Compound Detail

CHEMBL3989928

REZAFUNGIN ACETATE

💊 Approved Drug

Enter ChEMBL ID:

Free Research Context This compound will appear in recent viewed items on the research home for this browser.

💊 Approved Drug

CC(=O)[O-].CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](OCC[N+](C)(C)C)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1

ChEMBL ↗ Properties Compare Identifier

Basic Information

ChEMBL ID	CHEMBL3989928
Name	REZAFUNGIN ACETATE
Phase	Approved
Structure Type	MOL
InChI Key	MXMWJAPNUIKPGF-YOFVRWEXSA-N
Therapeutic	✓ Yes
Parent Compound	CHEMBL3989945
Active Moiety	CHEMBL3989945

Known Names

Acetate de rezafungine Acetato de rezafungina Biafungin acetate CD-101 ACETATE CD101 acetate Rezafungin acetate Rezzayo SP-3025 ACETATE

Targets

Activities

Assay Types

PK Parameters

Publications

Known Names

Indications

Mechanisms

Molecular Properties

1226.4

MW (Da)

Drug Information

Molecule Type	Small molecule
First Approval	2023
Availability	Prescription
Chirality	Single Enantiomer

Routes of Administration

Parenteral

Flags

Natural Product

USAN Stem	-fungin
USAN Year	2016

Extended Properties

Molecular Formula	C65H88N8O19
MW	1285.46

Mechanism of Action

Mechanism	Action Type	Target	Direct	Efficacy
Candida inhibitor	INHIBITOR	Candida	✓	✓

Indications

Candidemia Candidiasis Candidiasis, Invasive Pneumonia, Pneumocystis Mycoses

ATC Classification

J02AX08

rezafungin acetate

Level 1: ANTIINFECTIVES FOR SYSTEMIC USE

Level 2: ANTIMYCOTICS FOR SYSTEMIC USE

Data from ChEMBL 36 via Core Engine